Medpace Flags Rising Cancellations, Near-Term Growth Uncertain

Medpace reported Q1 EPS of $4.28 and revenue of $706.6 million, both above estimates, but the stock fell 21.9% as cancellations rose and backlog cancellations hit a more than one-year high. Net new business awards of $618.4 million produced a 0.88x book-to-bill, well below expectations, and management flagged limited visibility beyond the next two quarters. The company kept 2026 guidance unchanged at $16.68-$17.50 EPS and $2.755 billion-$2.855 billion in sales, while noting biopharma M&A remains a headwind.

Analysis

The market is likely pricing MEDP less as a one-quarter miss and more as an inflection in the durability of its growth algorithm. In CROs, cancellations matter more than reported revenue because they are an early read on sponsor confidence and future utilization; a sustained rise in oncology/cardiovascular churn suggests pipeline fragility is showing up first in the most valuable therapeutic areas. That creates a second-order risk that sales force productivity, pricing leverage, and margin stability all de-rate together over the next 2-3 quarters.

The bigger issue is that M&A commentary hints at a structural headwind rather than a cyclical blip. If the company is materially exposed to acquired programs being removed from the addressable work pool, then larger biotech/pharma deal activity could paradoxically suppress near-term order flow even while industry financing improves. That makes the stock unusually sensitive to deal headlines: in a risk-on biotech tape, MEDP may lag peers because M&A improves capital markets but worsens its work pipeline.

Consensus may be underestimating how much of the current multiple was supported by visibility, not just growth. A 0.88x book-to-bill in a business where backlog quality is the real asset can justify a 15-25% multiple reset if investors conclude the 2026 guide is a peak-margin number rather than a floor. The contrarian bullish case is that the selloff may overshoot if cancellations are concentrated in a small set of large studies and if re-booking normalizes by mid-year; that would give a sharp snapback, but only if the next two quarters show backlog conversion stabilizing rather than just revenue beating on timing.

Key Decisions for Investors

• Short MEDP on rallies for a 1-3 month horizon; use post-earnings volatility to enter only if price stabilizes above the first-day low. Risk/reward favors a further 10-15% downside if bookings remain sub-1.0x, with a tight cover point if management demonstrates cancellation normalization on the next call.
• Pair trade: long IQV / short MEDP for the next 1-2 quarters. IQV should be less exposed to a single-name bookings air pocket and offers cleaner leverage to broad biopharma spend recovery; the spread works if CRO multiples compress around backlog visibility rather than revenue beats.
• Buy MEDP put spreads 2-4 months out instead of outright short stock. Structure for another leg down tied to guidance revisions or weaker next-quarter awards; capped risk is preferable because a short-covering bounce is plausible if cancellations are transitory.
• Avoid adding to other small/mid-cap CROs until MEDP’s next bookings print. The read-through is that sponsor hesitation may be showing up first in outsourced development budgets, which could pressure peers with similar oncology exposure.
• Contrarian tactical long only on proof of re-acceleration: if book-to-bill recovers above 1.0x and cancellations normalize for one quarter, fade the bearish move with a 3-6 month horizon. Until then, the burden of proof is on management, not the stock.